SCHEMBL5714714

SCHEMBL5714714

O=C(Oc1ccc(Oc2ccc(C(F)(F)F)cn2)cc1)N1CCN(CCc2nccs2)CC1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 12/20 0.63
BCHE P06276 1/20 0.62
SCN9A Q15858 5/20 0.48
SCN10A Q9Y5Y9 1/20 0.48
CYP3A4 P08684 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SCN7A Q01118 2/20 0.46
KCNH2 Q12809 2/20 0.46
SCN5A Q14524 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714565 0.86 CYP3A4 (0.45) LIPEBCHECYP3A4SMN1; SMN2
SCHEMBL5714438 0.86 LIPE (0.45) LIPEBCHECYP3A4SMN1; SMN2
SCHEMBL5653247 0.86 LIPE (0.63) LIPEBCHESCN9ASCN10ACYP3A4
SCHEMBL6101868 0.85 TRPV1 (0.47) LIPEBCHECYP3A4SMN1; SMN2
SCHEMBL5648365 0.85 LIPE (0.67) LIPEBCHESCN9ASCN10ACYP3A4
SCHEMBL5647339 0.84 LIPE (0.74) LIPEBCHESCN9ASCN10ACYP3A4
SCHEMBL5651377 0.84 LIPE (0.71) LIPEBCHESCN9ASCN10ACYP3A4
SCHEMBL5645925 0.83 LIPE (0.73) LIPEBCHESCN9ASCN10ACYP3A4
SCHEMBL5652243 0.83 LIPE (0.64) LIPEBCHESCN9ASCN10ACYP3A4
SCHEMBL5714915 0.83 LIPE (0.61) LIPEBCHESCN9ASCN10ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL LIPE 1/4885BCHE 47/4885SCN9A 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.